补脾定元汤治疗脾虚型慢性精神分裂症临床疗效及安全性分析

Clinical Efficacy and Safety Analysis of Using Bupi Dingyuan Decoction in the Treatment of Patients with Spleen Deficiency Type Chronic Schizophrenia

目的:分析补脾定元汤治疗脾虚型慢性精神分裂症患者的临床疗效及安全性。方法:回顾性分析我院2018年12月~2020年10月收入治疗的122脾虚型慢性精神分裂症患者资料,根据治疗方式不同分为对照组(常规西医药物治疗)与研究组(常规西医药物治疗基础上予以补脾定元汤治疗),每组各61例。比较两组临床疗效、阳性与阴性症状量表(Positive And Negative Syndrome Scale,PANSS)评分、汉密顿抑郁量表(Hamilton Depression Scale,HAMD)及不良反应发生情况。结果:(1)研究组治疗后临床总有效率(96.72%)显著高于对照组总有效率(85.25%),两组间比较差异显著,存在统计学意义(P<0.05);(2)两组治疗后PANSS评分显著低于治疗前,且研究组治疗后PANSS评分较对照组低,差异存在统计学意义(P<0.05);(3)两组治疗后HAMD评分明显低于治疗前,且研究组治疗后HAMD评分较对照组低,差异存在统计学意义(P<0.05);(4)对照组不良反应发生率(13.11%)高于研究组不良反应发生率(3.28%),两组对比差异存在统计学意义(P<0.05)。结论:补脾定元汤治疗脾虚型慢性精神分裂症临床疗效显著,可有效改善患者精神症状,且不良反应发生情况少,安全性较高,具有临床使用价值。

Objective:To analyze the clinical efficacy and safety analysis of using Bupi Dingyuan Decoction in the treatment of patients with spleen deficiency type of chronic schizophrenia.Methods:The data of 122 patients with spleen deficiency type of chronic schizophrenia who were admitted to this hospital for treatment from December 2018 to October 2020 were retrospectively analyzed.According to the different treatment methods,they were divided into a controlled group(conventional western medicine treatment)and a study group(supplemented with Bupi Dingyuan Decoction),with 61 cases in each group.The clinical efficacy,the Positive and Negative Syndrome Scale(PANSS)score,the Hamilton Depression Scale(HAMD)and the incidence of adverse reactions were compared between the two groups.Results:(1)The total clinical effective rate of the study group after treatment(96.72%)was significantly higher than that of the controlled group(85.25%),and the difference between the two groups was statistically significant(P<0.05).(2)The PANSS scores of the two groups after treatment were significantly lower than those before treatment,and the PANSS score of the study group after treatment was lower than that of the controlled group,the difference was statistically significant(P<0.05).(3)The HAMD scores of the two groups after treatment were significantly lower than those before treatment,and the HAMD score of the study group after treatment was lower than that of the controlled group,the difference was statistically significant(P<0.05).(4)The incidence of adverse reactions in the controlled group(13.11%)was higher than that in the study group(3.28%),and the difference between the two groups was statistically significant(P<0.05).Conclusion:Using Bupi Dingyuan Decoction has significant clinical efficacy in the treatment of patients with spleen deficiency type chronic schizophrenia.It can effectively improve the patients’psychiatric symptoms and has fewer adverse reactions,indicating that its safety is high and it has clinical value.